Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Opus Genetics (IRD) Cash from Operations (2021 - 2024)

Opus Genetics (IRD) has disclosed Cash from Operations for 8 consecutive years, with 4548000.0 as the latest value for Q4 2023.

  • On a quarterly basis, Cash from Operations fell 84.2% to 4548000.0 in Q4 2023 year-over-year; TTM through Dec 2023 was 1112000.0, a 107.77% decrease, with the full-year FY2024 number at 25576000.0, down 2200.0% from a year prior.
  • Cash from Operations was 4548000.0 for Q4 2023 at Opus Genetics, up from 3003000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 28791000.0 in Q4 2022 to a low of 6170000.0 in Q1 2022.
  • A 3-year average of 47454.55 and a median of 3646000.0 in 2023 define the central range for Cash from Operations.
  • Biggest YoY gain for Cash from Operations was 125.96% in 2023; the steepest drop was 84.2% in 2023.
  • Opus Genetics' Cash from Operations stood at 3584000.0 in 2021, then surged by 903.32% to 28791000.0 in 2022, then crashed by 84.2% to 4548000.0 in 2023.
  • Per Business Quant, the three most recent readings for IRD's Cash from Operations are 4548000.0 (Q4 2023), 3003000.0 (Q3 2023), and 989000.0 (Q2 2023).